Muscle aspartyl protease (cathepsin P) activity: Detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells

Canadian Journal of Physiology and Pharmacology

Volumn 74, Issue 10, 1996, Pages 1141-1148

  Bolger, Gordon T ^a   Jaramillo, Jorge ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Aspartyl protease; Cachexia; Cathepsin D; Chromophoric substrate; Tumor

Indexed keywords

APROTININ; ASPARTIC PROTEINASE; BACITRACIN; CATHEPSIN D; EDETIC ACID; LEUPEPTIN; PEPSTATIN; PROTEINASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; LIVER; MALE; MOUSE; MUSCLE MASS; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKELETAL MUSCLE; SPLEEN; WEIGHT REDUCTION;

ANIMALS; CACHEXIA; CATHEPSIN D; ENDOTOXINS; ESCHERICHIA COLI; HINDLIMB; LEUKEMIA L1210; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED DBA; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; ORGAN SIZE; PEPSTATINS; PROTEASE INHIBITORS;

EID: 0030464091     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y96-117     Document Type: Article

References (37)

1. Argilés, J.M., Garcia-Martinez, C., Klovera, M., and López-Soriano, F.J. 1992. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med. Res. Rev. 12: 637-652.
2. Beutler, B. 1993. Cytokines and cancer cachexia. Hosp. Pract. 28: 45-52.
3. Beutler, B., and Cerami, A. 1988. Tumor necrosis, cachexia, shock and inflammation: a common mediator. Annu. Rex. Biochem. 57: 505-518.
4. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-253.
5. Cerami, A., Ikeda, Y., LeTrang., N., Hotez, P.J., and Beutler, B. 1985. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11: 173-177.
6. Dunn, B.M., Jimenez, M., Parten, B.F., Valler, M.J., Rolph, C.E., and Kay, J. 1986. A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem. J. 237: 899-906.
7. Fearon, K.C., and Preston, T. 1990. Body composition in cancer cachexia. Infusionstherapie, 17: 63-66.
8. Ferguson, W.W., Fidler, M.R., Folkmann, C.K., and Starling, M.D. 1979. Correlation of lysosomal enzymes and cachexia in the tumor-bearing rat. J. Surg. Res. 26: 150-156.
9. Gour-Salin, B.J., Lachance, P., Plouffe, C., Storer, A.C., and Ménard. R. 1993. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B. J. Med. Chem. 36: 720-725.
10. Greenbaum, L.M., and Sutherland, J.H.R. 1983. Host cathepsin D response to tumor in the normal and pepstatin treated mouse. Cancer Res. 43: 2584-2587.
11. Henry, K., Rathgaber, S., Sullivan, C., and McCabe, K. 1992. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann. Int. Med. 116: 53-54.
12. Hirsch, A.T., Pinto, Y.M., Schunkert, H., and Dzau, V.J. 1990. Potential role of tissue renin angiotensin system in the pathophysiology of congestive heart failure. Am. J. Cardiol. 66: 22D-32D.
13. Hocman, G. 1992. Chemoprevention of cancer: protease inhibitors. Int. J. Biochem. 24: 1365-1375.
14. Kirschke, H., and Barrett, A.J. 1987. Chemistry of lysosomal proteases. In Lysosomes: their role in protein breakdown. Edited by H. Glaumann and F.J. Ballard. Academic Press, London. pp. 193-238.
15. Langstein, H.N., and Norton, J.A. 1991. Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5: 103-123.
16. Lönnroth, C., Moldwaer, L.L., Gelin, J., Kindblom, L., Sherry, B., and Lundholm, K. 1990. Tumor necrosis factor-α and interleukin-1α production in cachetic, tumor-bearing mice. Int. J. Cancer, 46: 889-896.
17. Loprinzi, C.L., Goldberg, R.M., and Burnham, N.L. 1992a. Cancer-associated anorexia and cachexia. Implications for drug therapy. Drugs, 43: 499-506.
18. Loprinzi, C.A., Johnson, P.A., and Jensen, M. 1992b. Megestrol acetate for anorexia and cachexia. Oncology, 49: 46-49.
19. Lundholm, K., Bylund, A.-C., Holm, J., and Scherstén, T. 1976. Skeletal muscle metabolism in patients with malignant tumor. Eur. J. Cancer, 12: 465-473.
20. Lundholm, K., Edström, S., Ekman, L., Karlberg, I., Bylund, A.-C., and Scherstén, T. 1978. A comparative study of the influence of malignant tumor on host metabolism in mice and man. Cancer, 42: 453-461.
21. Miyazaki, M., Etoh, Y., Iizuka, K., and Toda, N. 1989. An orally active renin inhibitor cyclohexylnorstatine-containing dipeptide (KRI-1314). J. Hypertens. 7: S25-S27.
22. Mulligan, H.D., Mahony, S.M., Ross, J.A., and Tisdale, M.J. 1992. Weight loss in a murine cachexia model is not associated with the cytokines tumor necrosis factor-α or interleukin-6. Cancer Lett. 65: 239-242.
23. Nathwani, D., Green, S.T., Heslop, K.M., Goldberg, D.J., and Kennedy, D.H. 1990. Beneficial response to megestrol acetate in AIDS-related cachexia and a possible megestrol withdrawal-associated syndrome. Acta Dermato-Venereol. 70: 520-521.
24. Rhodes, J.M., and Andersen, A.B. 1993. Role of cathepsin D in the degradation of human serum albumin by peritoneal macrophages and veiled cells in antigen presentation. Immunol. Lett. 37: 103-110.
25. Sakai, H., Saku, T., Kato, Y., and Yamamoto, K. 1989. Quantitation and immunohistochemical localization of cathepsins E and D in rat tissues and blood cells. Biochim. Biophys. Acta, 991: 367-375.
26. Schmitt, M., Jänicke, F., and Graeff, H. 1992. Tumor-associated proteases. Fibrinolysis, 6(Suppl. 4): 3-26.
27. Shaheen, R.M., Miselkic, S., and Wittliff, J.L. 1993. Expression of cathepsin-D in human endometrial and ovarian carcinomas. Clin. Res. 42: 710A.
28. Szecsi, P.B. 1992. The aspartic proteases. Scand. J. Clin. Lab. Invest. 52(Suppl. 210): 5-22.
29. Tanaka, Y., Eda, H., Tanaka, T., Udagawa, T., Ishikawa, T., Horii, I., Ishitsuka, H., Kataoka, T., and Taguchi, T. 1990. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, Colon 26 adenocarcinoma. Cancer Res. 50: 2290-2295.
30. Torti, F.M., Dieckmann, B., Beutler, B., Cerami, A., and Ringold, G.M. 1985. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (Washington, D.C.), 229: 867-869.
31. Tracey, K.J., and Cerami, A. 1990. Metabolic responses to cachectin/TNF. A brief review. Ann. N.Y. Acad. Sci. 587: 325-331.
32. Tumminello, F.M., Bernacki, R.J., Gebbia, N., and Leto, G. 1993. Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. Med. Res. Rev. 13: 199-208.
33. Umezawa, H., Aoyagi, T., Morishima, H., Matsuzaki, M., Hamada, M., and Takeuchi, T. 1970. Pepstatin, a new pepsin inhibitor produced by actinomycetes. J. Antibiot. (Tokyo), 23: 259-262.
34. Wilmore, D.W. 1991. Catabolic illness: strategies for enhancing recovery. N. Engl. J. Med. 325: 695-702.
35. Wing, S.S., and Goldberg, A.L. 1993. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am. J. Physiol. 264: E668-E676.
36. Yamamoto, K., Sakai, H., Ueno, F., and Kato, Y. 1991. Biological significance and activity control of cathepsin E compared with cathepsin D. In Structure and function of the aspartic proteinases. Edited by B.M. Dunn. Plenum Press, New York. pp. 297-306.
37. Yonezawa, S., Fuji, K., Maejiman, Y., Tomato, K., Mori, Y., and Muto, N. 1988. Further studies on rat cathepsin D: subcellular localization and existence of the active subunit form. Arch. Biochem. Biophys. 267: 176-183.